점진적 단계 단축을 적용한 cetuximab 탈감작요법 사례 1예
A successful shortening of desensitization protocol in a patient with cetuximab anaphylaxis
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Desensitization therapy can help overcome severe hypersensitivity reactions and allow continuing administration of the culprit agents. However, this is time- and labor-intensive due to a prolonged infusion time and the serial adjustment of infusion rate between steps. Therefore, simplified protocols using fewer steps have been tested, although currently there is no established standard strategy. Cetuximab plays an important role in the treatment of metastatic colorectal cancer. Although cetuximab is well tolerated, severe infusion reactions occur in 1.1% of patients, and most occur within 1 hour of receiving the first dose. Here, we report a recent attempt to shorten the steps of gradual cetuximab desensitization. A 57-year-old male patient diagnosed with obstructive sigmoid colon cancer received cetuximab chemotherapy and experienced immediate anaphylaxis at the first cycle. A one-bag, 17-step desensitization protocol was applied to cetuximab administration. After the first successful desensitization cycle, the process of desensitization was shortened 1–2 step(s) per cycle, down to 2 steps, without a breakthrough reaction. The patient ultimately received regular infusions. Shortening of the rapid desensitization protocol can be considered if the previous cycle is well-tolerated, even in a patient who suffered previous anaphylaxis to cetuximab.
Abstract
Desensitization therapy can help overcome severe hypersensitivity reactions and allow continuing administration of the culprit agents. However, this is time- and labor-intensive due to a prolonged infusion time and the serial adjustment of infusion rate between steps. Therefore, simplified protocols using fewer steps have been tested, although currently there is no established standard strategy. Cetuximab plays an important role in the treatment of metastatic colorectal cancer. Although cetuximab is well tolerated, severe infusion reactions occur in 1.1% of patients, and most occur within 1 hour of receiving the first dose. Here, we report a recent attempt to shorten the steps of gradual cetuximab desensitization. A 57-year-old male patient diagnosed with obstructive sigmoid colon cancer received cetuximab chemotherapy and experienced immediate anaphylaxis at the first cycle. A one-bag, 17-step desensitization protocol was applied to cetuximab administration. After the first successful desensitization cycle, the process of desensitization was shortened 1–2 step(s) per cycle, down to 2 steps, without a breakthrough reaction. The patient ultimately received regular infusions. Shortening of the rapid desensitization protocol can be considered if the previous cycle is well-tolerated, even in a patient who suffered previous anaphylaxis to cetuximab.
참고문헌 (20)
- Owonikoko TK, "The role of cetuximab in the management of non-small-cell lung cancer", Clin Lung Cancer, 10, pp.230~238 (2009)
- Picard M, "Current knowledge and management of hypersensitivity reactions to monoclonal antibodies", J Allergy Clin Immunol Pract, 5, pp.600~609 (2017)
- Kang SP, "Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management", J Support Oncol, 5, pp.451~457 (2007)
- Chung CH, "Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1, 3-galactose", N Engl J Med, 358, pp.1109~1117 (2008)
- 원하경, "Cetuximab에 의한 아나필락시스를 보인 환자에서 성공적인 탈감작 적용 1예", Allergy Asthma & Respiratory Disease, 3(4), pp.294~296 (2015), 대한 소아알레르기 호흡기학회[DOI]
- Campos L, "Update on desensitization", Cur Treat Options Allergy, 6, pp.519~537 (2019)
- Caiado J, "Drug desensitizations for chemotherapy : safety and efficacy in preventing anaphylaxis", Curr Allergy Asthma Rep, 21, pp.37~ (2021)
- Chung CH, "Managing premedications and the risk for reactions to infusional monoclonal antibody therapy", Oncologist, 13, pp.725~732 (2008)
- Huscher D, "Dose-related patterns of glucocorticoid-induced side effects", Ann Rheum Dis, 68, pp.1119~1124 (2009)
- Sloane D, "Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies", J Allergy Clin Immunol Pract, 4, pp.497~504 (2016)
- de Las Vecillas Sanchez L, "Drug hypersensitivity and desensitizations : mechanisms and new approaches", Int J Mol Sci, 18, pp.1316~ (2017)
- Sung-Yoon Kang, "Desensitization for the prevention of drug hypersensitivity reactions", The Korean Journal of Internal Medicine, 37(2), pp.261~270 (2022), 대한내과학회[DOI]
- Bavbek S, "Rapid drug desensitization with biologics : a single-center experience with four biologics", Int Arch Allergy Immunol, 171, pp.227~233 (2016)
- Baselga J, "The EGFR as a target for anticancer therapy--focus on cetuximab", Eur J Cancer, 37(Suppl 4), pp.S16~S22 (2001)
- Schwartzberg LS, "Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices : assessment of clinical consequences", Support Care Cancer, 16, pp.393~398 (2008)
- Castells MC, "Hypersensitivity reactions to chemotherapy : outcomes and safety of rapid desensitization in 413 cases", J Allergy Clin Immunol, 122, pp.574~580 (2008)
- Tsao LR, "Hypersensitivity reactions to platinum agents and taxanes", Clin Rev Allergy Immunol, 62, pp.432~448 (2022)
- Lee JH, "A one-bag rapid desensitization protocol for paclitaxel hypersensitivity : a noninferior alternative to a multi-bag rapid desensitization protocol", J Allergy Clin Immunol Pract, 8, pp.696~703 (2020)
- Zirbs M, "A shortened docetaxel desensitization protocol for use in special cases", J Eur Acad Dermatol Venereol, 26, pp.391~393 (2012)
- Arnold DF, "Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1, 3-galactose", N Engl J Med, 358, pp.2735~2736 (2008)